newsfilter
← Latest News
Business Wire·

Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab

Baseline C-reactive Protein (CRP) <150 mg/L identified as the strongest predictor of response to lenzilumab in hospitalized COVID-19 patients In this population age <85 years, lenzilumab improved likelihood of survival without ventilation by 3-fol